Answers are grounded in this paper and cite their sources.
During the last decades, life science startup companies have relatively rapidly increased their presence in the pharmaceutical landscape. Pharmaceutical development has evolved because technology (analytical and process development) and clinical development (hybrid design in phase 1, including patients in phase 1B) have evolved in parallel allowing in certain cases to decrease the time to regulatory filings (IND, CTA, NDA, NDA 505 (b)(2),..), which seemed attractive for startup companies. .
No takes yet. Share an insight, caveat, or question.
Francois Xavier Lacasse (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: